Evidence map›Paper›PMID 41989506›Full record

Observational studyEsophagus : official journal of the Japan Esophageal Society2026

Japanese prospective registry study of particle therapy for esophageal cancer including comparison with clinical trials in Japan.

Takashi Ono, Hitoshi Ishikawa, Sunao Tokumaru, Toshinori Soejima, Tetsuro Isozaki, Takuya Kimoto, Hidehiro Hojo, Yuichi Hiroshima, Yosuke Takakusagi, Kazushi Maruo and 5 more

Abstract readMulticenter StudyComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takashi OnoDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, 7-172, Yatsuyamada, Koriyama, Fukushima, 963-8052, Japan. abc1123513@gmail.com.ORCID http://orcid.org/0000-0002-9711-1158
Hitoshi IshikawaNational Institutes for Quantum and Radiological Science and Technology, QST Hospital, 4-9-1 Anagawa, Inage-Ku, Chiba, 263-8555, Japan.
Sunao TokumaruDepartment of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Kouto, Shingu-Cho, Tatsuno, Hyogo, 679-5165, Japan.
Toshinori SoejimaDepartment of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Tetsuro IsozakiNational Institutes for Quantum and Radiological Science and Technology, QST Hospital, 4-9-1 Anagawa, Inage-Ku, Chiba, 263-8555, Japan.
Takuya KimotoDepartment of Radiology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto, 602-8566, Japan.
Hidehiro HojoDepartment of Radiation Oncology, National Cancer Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Yuichi HiroshimaRadiation Oncology & Proton Medical Research Center, Institute of Medicine, University of Tsukuba, 2-1-1, Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.
Yosuke TakakusagiDepartment of Radiation Oncology, Yokohama Sakae Kyosai Hospital, 132, Katsura, Sakae-Ku, Yokohama, Kanagawa, 247-8581, Japan.
Kazushi MaruoDepartment of Biostatistics, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Kensuke UmeharaNational Institutes for Quantum and Radiological Science and Technology, QST Hospital, 4-9-1 Anagawa, Inage-Ku, Chiba, 263-8555, Japan.
Takayuki HashimotoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Takashi KameiDepartment of Surgery, Graduate School of Medicine, Tohoku University, 1-1, Seiryomachi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.
Manabu MutoDepartment of Medical Oncology, Graduate School of Medicine, Kyoto University, 54, Shougoin Kawaharachou, Sakyo-Ku, Kyoto, 606-8507, Japan.
Hideyuki SakuraiRadiation Oncology & Proton Medical Research Center, Institute of Medicine, University of Tsukuba, 2-1-1, Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParticle therapy is gaining interest for treating esophageal cancer due to its ability to target tumors while minimizing radiation exposure to surrounding organs compared to X-ray therapy. While simulations show a favorable distribution with particle therapy, there is ongoing discussion regarding its impact on the prognosis of esophageal cancer. This study sought to assess the effectiveness of particle therapy in treating esophageal cancer by comparing it with previous clinical trials of X-ray therapy in Japan.

methodsThis was a multicenter, prospective, observational registry study, and particle therapy was performed in accordance with a unified treatment policy. For stage I and II/III cases, cases that met the eligibility criteria for the Japan Clinical Oncology Group 0502 and 0909 clinical trials were extracted, and the clinical results were compared.

resultsThe three-year overall survival rates were 94.7% and 84.9% for stage I and stage II/III cases, respectively. The three-year progression-free survival rates were 90.4% in stage I patients and 60.3% in stage II/III patients. No statistically significant differences were observed in overall survival or progression-free survival when comparing registry data with the two Japan Clinical Oncology Group studies. No grade 3 or higher cardiopulmonary toxicities were observed in the registry data.

conclusionsThis study analyzed nationwide registry data, and particle therapy is a safe treatment regarding toxicity for esophageal cancer, although further investigation into its effectiveness is needed.

Indexed as

Esophageal NeoplasmsProton TherapyAgedAged, 80 and overClinical Trials as TopicEast Asian PeopleFemaleHumansJapanMaleMiddle AgedNeoplasm StagingProgression-Free SurvivalProspective StudiesRegistriesSurvival RateCarbon-ion radiotherapyEsophageal cancerParticle therapyProton beam therapy

Identifiers

PMID41989506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.